3D Bioprinted Human Tissue Market Size

3D Bioprinted Human Tissue Market Analysis

The 3D bioprinted human tissue market is expected to register a CAGR of 20.7% during the forecast period.

The COVID-19 pandemic has spread across various countries, leading to a global health system overload. The increasing number of patients, along with supply chain disruption, generated a shortage of medical devices and personal protective equipment. As per an April 2021 published article by Medical Device + Diagnostic Industry (MD+DI), in the battle against COVID-19, 3D printer companies specializing in a range of services pivoted their technology and designs to support relief efforts, mass-producing medical products essential for providers in a pandemic. As shortages of personal protective equipment persisted during the coronavirus pandemic, 3D printing helped to alleviate some of the gaps.

However, according to a New York Times article published in July 2020, Wake Forest Institute for Regenerative Medicine used the process more innovatively, creating tiny replicas of human organs, some as small as a pinhead, to test drugs to fight COVID-19. Owing to the increasing 3D printing innovation in drug testing for COVID-19, the market is likely to continue its significant growth rate during the forecast period at a pre-pandemic rate.

Specific factors driving the market growth include technological advancements leading to enhanced application and rising demand for customized 3D bioprinted tissue engineering and organ replacement. An article published by ScienceDirect in March 2022 states that 3D bioprinting has served as a promising approach for engineering complex tissues, offering precise control over cellular building blocks to recapitulate the intricate hierarchy and complexity of native human tissues.

Recent advancements in the innovative forms of living building blocks and enabling bioprinting techniques have greatly expanded the capability to engineer more complex and functional tissues, and further extend their applications in engineering disease models, microphysiological systems, and biobots. Furthermore, according to an article published by Science Daily in March 2021, researchers at Lund University in Sweden have designed a new bio-ink that allows small human-sized airways to be 3D bioprinted with the help of patient cells. The 3D-printed constructs are biocompatible and support new blood vessel growth into the transplanted material. Therefore, such advancements are expected to increase the demand for 3D bioprinted human tissues, thus driving the market.

Furthermore, the increasing product innovation and collaborations funded by the key market players and government agencies will support the market growth over the forecast period. In November 2022, Northrop Grumman's 18th Commercial Resupply Services (NG-18) mission launched an upgraded version of Redwire Space's BioFabrication Facility (or BFF), a 3D bioprinter capable of printing human tissue. The project, sponsored by the ISS National Laboratory, paved the way for in-space bioprinting tissues to help patients back on Earth. Such product innovations are also adding to the growth of the market.

Thus, the abovementioned factors are impacting the market growth of the 3D bioprinted human tissue market. However, the shortage of skilled professionals and the absence of specific regulatory guidelines are expected to hinder market growth over the forecast period.